Tag Archives: Geulah Livshits

Achilles Therapeutics (ACHL) Received its Third Buy in a Row

After Oppenheimer and Piper Sandler gave Achilles Therapeutics (NASDAQ: ACHL) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics today and set a price

Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX)

In a report issued on April 1, Geulah Livshits from Chardan Capital reiterated a Buy rating on Immatics (IMTX – Research Report). The company’s shares closed last Thursday at $11.64. According to TipRanks.com, Livshits is a top 100 analyst with

Cabaletta Bio (CABA) Receives a Rating Update from a Top Analyst

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Cabaletta Bio (CABA – Research Report) today and set a price target of $21.00. The company’s shares closed last Thursday at $13.07. According to TipRanks.com, Livshits is a top 25

Chardan Capital Remains a Buy on Immatics (IMTX)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immatics (IMTX – Research Report) today and set a price target of $28.00. The company’s shares closed last Thursday at $9.31, close to its 52-week low of $8.67. According to

Chardan Capital Thinks Immatics’ Stock is Going to Recover

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immatics (IMTX – Research Report) today and set a price target of $28.00. The company’s shares closed last Tuesday at $10.00, close to its 52-week low of $9.51. According to

Chardan Capital Reiterates Their Buy Rating on Moderna (MRNA)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Moderna (MRNA – Research Report), with a price target of $95.00. The company’s shares closed last Tuesday at $68.97. According to TipRanks.com, Livshits is a